Rather than continuing down the path toward price controls, Congress and the Administration should focus on removing current anti-competitive and anti-innovation regulations.
About a month ago, the Centers for Medicare & Medicaid Services announced the next 15 drugs that will be subject to the maximum fair price (MFP) negotiation process.
These negotiations are essentially a means to impose price controls on selected medicines.
If the Trump Administration truly wants to help patients, it would abandon these efforts and focus on regulatory reform.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Fixing The Regulatory Flaws Biosimilars Face Will Help Patients
Wayne Winegarden
Rather than continuing down the path toward price controls, Congress and the Administration should focus on removing current anti-competitive and anti-innovation regulations.
About a month ago, the Centers for Medicare & Medicaid Services announced the next 15 drugs that will be subject to the maximum fair price (MFP) negotiation process.
These negotiations are essentially a means to impose price controls on selected medicines.
If the Trump Administration truly wants to help patients, it would abandon these efforts and focus on regulatory reform.
Read the op-ed here:
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.